RHOD Antibody

Basic Research Questions

• What is RHOD and what are its primary cellular functions?

  RHOD (Rho-related GTP-binding protein RhoD) is a member of the small GTPase superfamily with diverse roles in cellular function. It is involved in endosome dynamics, coordinating membrane transport with cytoskeletal function, and participating in the internalization and trafficking of activated tyrosine kinase receptors such as PDGFRB . RHOD plays a critical role in actin cytoskeleton reorganization, regulating filopodia formation and actin filament bundling . Research has shown that RHOD has a distinct role in actin dynamics compared to better-studied Rho members like Cdc42, RhoA, and Rac1 . RHOD interacts with WHAMM (WASp homologue associated with actin Golgi membranes and microtubules) and FILIP1 (filamin A–binding protein) to coordinate Arp2/3-dependent and FLNa-dependent mechanisms controlling the actin filament system, cell adhesion, and cell migration .

• How do researchers validate RHOD antibody specificity in experimental systems?

  Validating RHOD antibody specificity involves multiple approaches:

  • Western blot analysis: Researchers should observe a band at the predicted molecular weight of 23 kDa . Validation should include positive controls like MCF-7, Raw264.7, and H9C2 cell lysates that express RHOD .

  • Immunocytochemistry: Compare staining patterns with known RHOD subcellular localization, particularly in the perinuclear area as observed in human BJ/SV40T fibroblasts .

  • siRNA knockdown controls: The effectiveness of RHOD-specific antibodies can be confirmed by demonstrating loss of signal in cells treated with RHOD-targeting siRNAs .

  • Cross-reactivity testing: Test antibodies against related Rho family proteins to ensure specificity, especially against close family members like Rif with which RHOD shares evolutionary history .

• What are the recommended applications and dilutions for RHOD antibodies in research?

  Based on validated RHOD antibodies, the following applications and dilution ranges are recommended:

  Application	Recommended Dilution	Notes
  Western Blot (WB)	1:500-1:1000	Optimal for detecting the 23 kDa RHOD protein
  Immunocytochemistry (ICC)	1:50-1:200	Effective for visualizing subcellular localization
  Immunoprecipitation (IP)	1:50-1:200	For protein-protein interaction studies

  When using anti-RHOD antibodies, researchers should optimize conditions based on their specific experimental system. For Western blot applications, prepare lysates from relevant cell types like human fetal liver samples or cell lines known to express RHOD . For immunofluorescence applications, standardize fixation methods (typically 3% paraformaldehyde in PBS for 25 minutes at 37°C) and permeabilization conditions (0.2% Triton X-100 for 5 minutes) .

Advanced Research Questions

• How do RHOD antibodies help elucidate the role of RHOD in actin dynamics and cell migration?

  RHOD antibodies have been instrumental in understanding RHOD's function in cytoskeletal regulation:

  • Phenotypic analysis: Immunostaining with RHOD antibodies has revealed that cells expressing constitutively active RHOD/G26V exhibit increased filopodia formation and distinctive short, multidirectional actin bundles compared to control cells with conventional stress fibers .

  • Knockdown studies: RHOD antibodies validate siRNA-mediated knockdown efficiency, allowing researchers to observe resulting phenotypes including accumulation of thick cortical actin bundles, increased focal adhesion size, and enhanced edge ruffling .

  • Functional assays: Cell migration assays combined with RHOD antibody-validated knockdowns have shown that RHOD and its effector WHAMM are required for directed cell migration, with knockdown cells showing only 50-60% wound closure compared to control cells .

  • Mechanistic studies: RHOD antibodies help researchers investigate the molecular mechanisms by which RHOD coordinates with WHAMM to regulate actin dynamics, revealing that WHAMM acts downstream of RHOD in this pathway .

• What methodologies are used to investigate RHOD's interactions with its binding partners?

  Several complementary techniques are employed to study RHOD's protein-protein interactions:

  • Co-immunoprecipitation: Using RHOD antibodies to pull down protein complexes, researchers have identified binding partners including WHAMM and FILIP1 . The recommended dilution for immunoprecipitation is 1:50-1:200 .

  • GST pulldown assays: These assays have been used to demonstrate direct binding between RHOD and its effectors, providing evidence that RHOD binds the actin nucleation-promoting factor WHAMM .

  • Immunofluorescence co-localization: RHOD antibodies combined with antibodies against potential interaction partners can visualize co-localization in cellular compartments, supporting biochemical interaction data .

  • Functional validation: Knockdown of putative RHOD interactors (like WHAMM) followed by phenotypic comparison with RHOD knockdown helps establish functional relationships in pathways controlling cytoskeletal dynamics and cell migration .

  • Domain mapping: By using RHOD antibodies in conjunction with truncated constructs of interaction partners, researchers can identify specific binding domains mediating these interactions .

• How can researchers distinguish between active and inactive forms of RHOD in their experiments?

  Distinguishing between active (GTP-bound) and inactive (GDP-bound) RHOD requires specialized approaches:

  • Activity-specific antibodies: While standard RHOD antibodies like EPR7027 detect total RHOD protein , researchers studying activation states often use mutant forms (constitutively active RHOD/G26V or dominant-negative RHOD/T31N) as experimental tools .

  • GTPase activation assays: These biochemical assays isolate active GTP-bound RHOD using the binding domains of effector proteins, followed by detection with RHOD antibodies.

  • Subcellular localization: Active RHOD exhibits distinct localization patterns that can be visualized with immunofluorescence using RHOD antibodies. For example, endogenous RHOD localizes primarily to the perinuclear area in fibroblasts .

  • Effector binding assays: Since active RHOD binds its effectors like WHAMM and FILIP1, co-immunoprecipitation efficiency can serve as an indirect measure of activation status.

  • Phenotypic analysis: Comparing cells expressing RHOD/G26V (active) versus RHOD/T31N (inactive) reveals distinct morphological phenotypes—filopodia and short actin bundles versus edge ruffles/lamellipodia, respectively .

• What are the current challenges in studying RHOD's role in vesicular transport using antibody-based approaches?

  Researchers face several challenges when investigating RHOD's function in vesicular transport:

  • Temporal dynamics: RHOD's involvement in endosome motility requires capturing dynamic processes. This necessitates advanced live-cell imaging techniques in conjunction with either fluorescently tagged RHOD or antibody-based detection in fixed samples at precise time points.

  • Distinguishing RHOD from related proteins: RHOD shares evolutionary history with Rif , requiring carefully validated antibodies that don't cross-react with related family members.

  • Context-dependent interactions: RHOD interacts with different partners in various cellular contexts, including diaphanous-related formin hDia2C in endosomal vesicle motility . Capturing these diverse interactions requires multiple experimental approaches.

  • Subcellular resolution: Since RHOD functions at specific subcellular locations, super-resolution microscopy techniques may be needed to precisely localize RHOD using antibodies.

  • Integration with other pathways: RHOD intersects with multiple signaling pathways, including interactions with Semaphorin receptors PlexinA1 and PlexinB1 and components of the TGF-β signaling pathway . Dissecting these complex relationships requires sophisticated experimental designs.

• How has RHOD research contributed to our understanding of cancer cell migration and metastasis?

  RHOD's role in cancer biology is an emerging field where RHOD antibodies play a critical investigative role:

  • Migration and invasion studies: Since RHOD regulates cell migration , RHOD antibodies help researchers investigate cancer cell motility. When RHOD expression is knocked down and validated by antibody detection, cells show approximately 50% reduction in wound closure capacity .

  • Cytoskeletal remodeling in cancer cells: Cancer progression often involves changes in actin dynamics. RHOD antibodies help visualize how RHOD-dependent actin remodeling might contribute to cancer cell phenotypes, particularly through its effects on filopodia formation and stress fiber dissolution .

  • Receptor trafficking: RHOD is involved in the internalization and trafficking of activated tyrosine kinase receptors like PDGFRB , which are often dysregulated in cancer. RHOD antibodies help track these processes in cancer cells.

  • Interaction with tumor suppressor pathways: RHOD interacts with components of the TGF-β signaling pathway , which has complex roles in cancer progression. RHOD antibodies facilitate investigation of these interactions.

  • Expression correlation studies: Immunohistochemistry with RHOD antibodies on tissue microarrays allows researchers to correlate RHOD expression with cancer progression, metastasis, and patient outcomes.

Clinical Research Questions

• How do Rh(D) immune globulin antibodies prevent Rhesus alloimmunization?

  Rh(D) immune globulin (RhIG) prevents Rhesus alloimmunization through several mechanisms:

  • Antigenic masking: RhIG antibodies bind to Rh(D) antigens on fetal red blood cells that have entered the maternal circulation, effectively masking them from recognition by the maternal immune system .

  • Accelerated clearance: The antibody-coated fetal red blood cells are rapidly cleared from the maternal circulation by the mononuclear phagocytic system, primarily macrophages, before the maternal immune system can mount a response .

  • FcR-mediated immunomodulation: RhIG activates inhibitory Fc receptors on B cells, suppressing antibody production. This may involve alterations in antigen processing and presentation .

  • Cytokine modulation: In vitro studies have demonstrated that anti-D coated red blood cells enhance secretion of interleukin 1 receptor antagonist, resulting in down-regulation of FcγR-mediated phagocytosis .

  Clinical data show remarkable efficacy—anti-D administration after childbirth reduces the risk of RhD alloimmunization six months after birth (risk ratio 0.04, 95% CI 0.02 to 0.06) and in subsequent pregnancies (risk ratio 0.12, 95% CI 0.07 to 0.23) .

• What methodological considerations are important when designing experiments to study RHOD's evolutionary conservation?

  When investigating RHOD's evolutionary conservation, researchers should consider:

  • Phylogenetic analysis: From an evolutionary perspective, Rif is present in eukaryotes from Drosophila onward, while a gene duplication event resulting in RHOD appears to have occurred specifically in mammals . This necessitates careful species selection for comparative studies.

  • Cross-species antibody validation: When using RHOD antibodies across species, validation is essential. Some antibodies like the A05942 antibody have been validated for reactivity to RHOD in Human, Mouse, and Rat samples .

  • Conserved domain analysis: Focus on functionally important domains that show higher conservation. RHOD antibodies targeting the N-terminal region (like EPR7027) may recognize conserved epitopes.

  • Functional conservation testing: Compare RHOD's role in processes like actin dynamics and endosome motility across species using homologous experimental systems.

  • Interaction partner conservation: Determine whether RHOD binding partners like WHAMM and FILIP1 are similarly conserved across species, as this might indicate functional conservation of RHOD-dependent pathways.

  • Technical controls: Include appropriate positive controls for each species tested, and consider creating species-specific validation datasets for antibody specificity.

• What are the latest developments in using Rh(D) antibodies for treating immune thrombocytopenic purpura?

  Rh(D) immune globulin therapy for immune thrombocytopenic purpura (ITP) has several important aspects:

  • Mechanism of action: In Rh-positive patients with ITP, Rh(D) immune globulin increases platelet counts by providing antibody-coated red blood cells as alternative targets for macrophage clearance, thereby reducing destruction of antibody-coated platelets .

  • FcR blockade mechanism: Treatment causes down-regulation of FcγRIIIa on splenic macrophages, which reduces their ability to destroy platelets. This represents an opposing effect from what might be predicted with intravenous Rho IgG .

  • Cytokine modulation: Enhanced secretion of interleukin 1 receptor antagonist from monocytes and granulocytes exposed to anti-D coated red blood cells may contribute to down-regulation of FcγR-mediated phagocytosis .

  • Safety monitoring: Due to risks of intravascular hemolysis (IVH), patients must be closely monitored for at least 8 hours after administration, with dipstick urinalysis at baseline, 2 hours, 4 hours, and prior to the end of the monitoring period .

  • Administration protocols: For ITP treatment, Rh(D) immune globulin is administered intravenously, unlike its intramuscular administration for prevention of Rh alloimmunization .

• How can researchers analyze RHOD's impact on focal adhesion dynamics?

  To study RHOD's effect on focal adhesions, researchers can employ these methodologies:

  • Immunofluorescence co-localization: Use RHOD antibodies alongside focal adhesion markers (like paxillin or vinculin) to visualize changes in focal adhesion size and distribution. Research has shown that cells treated with RHOD-specific siRNAs display a significant increase in focal adhesion size .

  • Adhesion assays: RHOD knockdown (validated with antibodies) results in increased cell attachment. In experimental models, cells knocked down for RHOD exhibited significantly better adhesion after 2 hours compared to control cells .

  • Live-cell imaging: Combine RHOD antibody validation with real-time focal adhesion visualization using fluorescently tagged adhesion proteins to capture dynamic changes.

  • Biochemical quantification: Use RHOD antibodies to confirm knockdown efficiency, then quantify focal adhesion components by Western blotting to measure changes in adhesion complex formation.

  • Molecular pathway analysis: Investigate RHOD's interaction with WHAMM and FILIP1, which appear to act downstream of RHOD in pathways controlling cell attachment .

  • Mechanical force measurements: Combine RHOD manipulation with traction force microscopy to determine how RHOD affects the mechanical properties of focal adhesions.